KPTI News and Press, Karyopharm Therapeutics Inc. From 02/11/21

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Karyopharm Therapeutics Inc. 2020 Q4 - Results - Earnings Call Presentation

Karyopharm Therapeutics (KPTI) Q4 results:Revenues: $35.1M (+93.9%); Xpovio Sales: $20M; License and other revenue: $14.8M.Net loss: ($43.4M) (-11%); loss/share: ($0.59) (-22%).2021 Financial Outlook: non-GAAP R&D and SG&A expenses to be in the range of $280M to $300M.Q1 Out...

Karyopharm Therapeutics (KPTI): Q4 GAAP EPS of -$0.59 in-line.Revenue of $35.1M (+93.9% Y/Y) beats by $5.41M.Q4 XPOVIO net sales of $20.2M.The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as...

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress -- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Pro...

KPTI is doing well with selinexor, with additional approvals and increasing sales. There are additional label expansions in the offing. The stock seems undervalued at current prices. For further details see: Karyopharm: Strong Potential, Low Price, Looks Investible

Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021 -- Conference Call Scheduled for Thursday, February 11, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutic...

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma PR Newswire NEWTON, Mass. , Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (...

We share the remaining top pick ideas from our Marketplace contributors. There are a wide variety - including biotech, precious metals, dividend, and energy ideas. Later on this week we will share the public Google Sheet that will track the performance of these ideas in real-time....

A support level has formed in the chart of Karyopharm Therapeutics Inc (KPTI). If the stock moves under this level, a breakdown could soon occur. Read more to learn to how to take advantage of this trade. A key support level has emerged in the chart of Karyopharm Therapeutics Inc ( KPTI )...

KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC ...